Furthermore, flow cytometric analysis showed that the percentage of AML cells (CD33+ cells) in the peripheral blood and spleens was lower in the LukS-PV treatment group than in the control group (Figures 1C, D). Here, CD33 is linked to acute myeloid leukemia.